Plain English Summary

Not provided at time of registration

Trial website

http://www.meningvax.org

Contact information

Type

Scientific

Primary contact

Dr Marie-Pierre Preziosi

ORCID ID

Contact details

Initiative for Vaccine Research
World Health Organization (WHO)
Department of Immunisation
Vaccines and Biologicals (IVB)
20 Avenue Appia
Geneva-27
CH-1211
Switzerland
+41 (0)22 791 3744
preziosim@who.int

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

RPC217; PsA-TT-003

Study information

Scientific title

Acronym

Study hypothesis

To compare the immunogenicity of a single dose of the PsA-TT vaccine with that of the Meningococcal A component of the PsACWY vaccine at 28 days after vaccination.

Ethics approval

Ethics approval received from:
1. The Gambia Government/Medical Research Council (MRC) Laboratories Joint Ethic Committee on the 30th July 2007 (ref: L2007.56)
2. Ethics committee of the National Center for Scientific Research (Centre National de la Recherche Scientifique [CNRS]) on the 8th August 2007 (ref: 127MSPM/DS/CNRS)
3. Ethics committee of the Faculty of Medicine Pharmacy and Odonto-stomatology (Faculte de Medecine de Pharmacie et d'Odonto-Stomatologie [FMPOS]) on the 23rd July 2007 (ref: 0750/FMPOS)

Study design

Phase II/III, observer-blind, randomised, active controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Condition

Bacterial meningitis

Intervention

1. One 0.5 ml dose out of a decadose vial of PsA-TT vaccine will be injected intramuscularly (IM) in the right deltoid
2. One 0.5 ml dose of PsACWY vaccine will be injected IM in the right deltoid

Joint sponsor:
Program for Appropriate Technology in Health (PATH) (USA)
1455 NW Leary Way
Seattle
WA 98107
U.S.A.
Tel: +1 206 285 3500
Fax: +1 206 285 6619

Principal Investigators:
Dr Samba Sow (PI for Mali)
Centre pour les Vaccins en Developpement (CVD) Mali
Centre National d'Appui a la lutte contre la Maladie (CNAM)
Ministere de la Sante
Ex-Institut Marchoux
BP 251 Bamako
Mali
Tel: +223 (0)674 8947
Fax: +223 (0)222 2883
Email: ssow@medicine.umaryland.edu

Dr Brown Okoko (PI for The Gambia)
Medical Research Council (MRC) Laboratories
PO Box 273
Fajara
The Gambia
Tel: +220 (0)779 2510
Fax: +220 (0)449 6513
Email: bokoko@mrc.gm

Dr Aldiouma Diallo (PI for Senegal)
Institut de Recherche pour le Développement (IRD)
BP 1386
CP 18524 Dakar
Senegal
Tel: +220 (0)654 1333
Email: diallo@ird.sn

Intervention type

Drug

Phase

Phase II/III

Drug names

Meningococcal A conjugate vaccine (PsA-TT), meningococcal ACWY polysaccharide vaccine

Primary outcome measures

The percentage of subjects who show a seroconversion for anti-Meningococcal Polysaccharide A (MenPsA) antibodies, i.e. a four-fold increase in post-immunisation serum titre with respect to pre-immunisation serum titre, at 28 days after a single vaccine dose, as measured by rabbit complement Serum Bactericidal Assay (rSBA).

Secondary outcome measures

Safety:
1. The percentage of subjects with local and systemic post-immunisation reactions during the first four days, adverse events and Serious Adverse Events (SAEs), as measured at 4 and 28 days after vaccination (reactogenicity and short-term safety)
2. The percentage of subjects with SAEs during the entire study duration, as measured at 182 days (6 months) and 364 days (1 year) (long-term safety)

Immunogenicity:
1. The percentage of subjects with anti-MenPsA titre greater than or equal to 1:8 (defined as seroprotection to MenA) at 28 days after a single vaccine dose, as measured by rSBA assay. The percentage of subjects with anti-MenPsA titer greater than or equal to 1:128 (defined as long-term seroprotection to MenA) will be also considered
2. Geometric Mean Titres (GMTs) for anti-MenPsA antibodies at 28 days after a single vaccine dose, as measured by rSBA assay
3. Evaluation of reverse cumulative distribution curves for MenPsA antibody titres at 28 days after a single vaccine dose, as measured by rSBA assay
4. The percentage of subjects who show a seroconversion for anti-MenPsA total Immunoglobulin G (IgG), i.e. a two-fold increase in post-immunisation serum concentration with respect to pre-immunisation serum concentration, at 28 days after a single vaccine dose, as measured by Enzyme-Linked Immunosorbent Assay (ELISA). The percentage of subjects with a four-fold increase in post-immunisation serum concentration with respect to pre-immunisation serum concentration will be also considered

Overall trial start date

20/08/2007

Overall trial end date

20/09/2008

Reason abandoned

Eligibility

Participant inclusion criteria

A subject will be eligible for inclusion if ALL of the following apply at the time of enrolment:
1. Age 2 to 29 years of age (both included)
2. Written informed consent obtained from the subject (for subjects equal to 18 years of age)/parents or legal guardian (for subjects less than 18 years of age)
3. Written informed assent from the subject if and as appropriate within the participating community (e.g., for subjects equal to 13 years of age in the Malian site, for subjects equal to 15 years of age in the Senegal site or for subjects equal to 12 years of age in the Gambia site)
4. Free of obvious health problems as established by medical history including physical examination and clinical judgement of the investigator
5. Subject/parents, or legal guardian capable and willing to come/bring their child or to receive home visits for all follow-up visits
6. Residence in the study area
7. Fully vaccinated according to the local Expanded Program on Immunisation (EPI) schedule (for subjects 2 to 3 years of age only)

Participant type

Patient

Age group

Not Specified

Gender

Both

Target number of participants

900

Participant exclusion criteria

Subjects with any of the following criteria at study entry will not be eligible for participation:
1. Previous vaccination against Neisseria meningitidis during the six previous years
2. Known exposure to Neisseria meningitidis during the three previous months
3. History of allergic disease or known hypersensitivity to any component of the two study vaccines and/or following administration of vaccines included in the local program of immunisation
4. Administration of any other vaccine within 60 days prior to administration of study vaccines or planned vaccination during the first 28 days after the study vaccination
5. Use of any investigational or non-registered drug within 90 days prior to the administration of study vaccines
6. Administration of immunoglobulins and/or any blood products within 30 days prior to the administration of study vaccines or planned administration during the study period
7. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents within 90 days prior to the administration of study vaccines (Including systemic corticosteroids, this means prednisone, or equivalent, greater than 0.5 mg/kg/day; topical steroids including inhaled steroids are allowed)
8. A family history of congenital or hereditary immunodeficiency
9. History of meningitis or seizures or any neurological disorder
10. Major congenital defects or serious chronic illness, including malnutrition (as per investigator's judgement)
11. Acute disease at the time of enrolment (acute disease is defined as the presence of a moderate or severe illness with or without fever) is a temporary exclusion
12. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination or laboratory tests, which in the opinion of the investigator, might interfere with the study objectives
13. Any condition or criteria that in the opinion of the investigator might compromise the well being of the subject or the compliance with study procedures or interfere with the outcome of the study
14. Non residence in the study area or intent to move out within one year
15. Pregnancy or lactation (a negative pregnancy test will be required before vaccination for all women of childbearing potential)
16. Previous inclusion of five family members in the study (i.e., subjects belonging to the same family - biological father, mother, child, and brothers and sisters may be included up to a maximum of five members from the same family)

Recruitment start date

20/08/2007

Recruitment end date

20/09/2008

Locations

Countries of recruitment

Gambia, Mali, Senegal

Trial participating centre

Initiative for Vaccine Research
Geneva-27
CH-1211
Switzerland

Sponsor information

Organisation

Serum Institute of India Limited (SIIL) (India)

Sponsor details

212/2
Hadapsar
Pune
411 028
India

Sponsor type

Industry

Website

http://www.seruminstitute.com/

Funders

Funder type

Charity

Funder name

Bill and Melinda Gates Foundation (USA)

Alternative name(s)

Funding Body Type

private sector organisation

Funding Body Subtype

foundation

Location

United States of America

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

1. 2011 results in http://www.ncbi.nlm.nih.gov/pubmed/21675889

Publication citations

  1. Results

    Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, Tapia M, Akinsola AK, Arduin P, Findlow H, Elie C, Haidara FC, Adegbola RA, Diop D, Parulekar V, Chaumont J, Martellet L, Diallo F, Idoko OT, Tang Y, Plikaytis BD, Kulkarni PS, Marchetti E, LaForce FM, Preziosi MP, Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans., N. Engl. J. Med., 2011, 364, 24, 2293-2304, doi: 10.1056/NEJMoa1003812.

Editorial Notes